Skip to content
DraconiticResearch
Search Sources API
203,952 studies31 sourcesUpdated 11 min ago
Peer-reviewedLicence not stated

Pembrolizumab (Keytruda): Indication: Pembrolizumab, in combination with enfortumab vedotin, as neoadjuvant treatment and then continued after radical cystectomy as adjuvant treatment, is indicated for the treatment of adult patients with MIBC who are ineligible for cisplatin-containing chemotherapy: Reimbursement Recommendation

Read full textCite

Related

  1. TroFuse-032 study design: pembrolizumab plus sacituzumab tirumotecan or chemotherapy followed by pembrolizumab plus chemotherapy as neoadjuvant therapy for early-stage, triple-negative breast cancer or HR-low+/HER2− breast cancer
    Peter Schmid, Javier Cortes, Rina Hui +9
    Future OncologyPeer-reviewedCC BY-NC-ND 4.0Full textOncologyPMC
  2. Garsorasib (D-1553) in Combination With Pembrolizumab and Chemotherapy for First-Line Metastatic NSCLC With KRAS G12C Mutation: Results of a Phase 1b Study.
    Dong Yan, Chaoying Liu, Xingya Li +10
    JTO clinical and research reportsPeer-reviewedCC BY-NC-NDFull textOncologyEurope PMC
  3. Inebilizumab (Uplizna): Indication: Adults with immunoglobulin G4-related disease: Reimbursement Recommendation
    Peer-reviewedLicence not statedFull textEurope PMC
  4. Vamorolone (Agamree): Indication: For the treatment of Duchenne muscular dystrophy in patients 4 years of age and older: Reimbursement Recommendation
    Peer-reviewedLicence not statedFull textEurope PMC
  5. Inebilizumab (Uplizna): Indication: As an add-on to standard therapy for the treatment of gMG in adult patients who are AChR or MuSK antibody positive: Reimbursement Recommendation
    Peer-reviewedLicence not statedFull textEurope PMC

Cite

BibTeXRIS
BibTeX
@article{anon2026pembrolizumab,
  title = {{Pembrolizumab (Keytruda): Indication: Pembrolizumab, in combination with enfortumab vedotin, as neoadjuvant treatment and then continued after radical cystectomy as adjuvant treatment, is indicated for the treatment of adult patients with MIBC who are ineligible for cisplatin-containing chemotherapy: Reimbursement Recommendation}},
  year = {2026},
  month = sep,
  url = {https://europepmc.org/article/MED/42899951},
}
RIS
TY  - JOUR
TI  - Pembrolizumab (Keytruda): Indication: Pembrolizumab, in combination with enfortumab vedotin, as neoadjuvant treatment and then continued after radical cystectomy as adjuvant treatment, is indicated for the treatment of adult patients with MIBC who are ineligible for cisplatin-containing chemotherapy: Reimbursement Recommendation
PY  - 2026
DA  - 2026/09/01
UR  - https://europepmc.org/article/MED/42899951
ER  -